In order to support the newly planned clinical trial programs in breast cancer and CRC, ALX Oncology (ALXO) has conducted a strategic prioritization and resource optimization exercise resulting in substantial decreases in preclinical research investments, including an approximately 30% workforce reduction primarily in the preclinical research function. As a result, ALX Oncology now expects its cash runway to extend into Q4 of 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology will highlight progress across its clinical pipeline
- ALXO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ALX Oncology price target lowered to $5 from $25 at H.C. Wainwright
- ALX Oncology presents updated data from ASPEN-06 Phase 2 trial
- ALX Oncology Strengthens Leadership with Key Appointments